Transforming Growth Factor-β Inhibition and Endothelin Receptor Blockade in Rats with Monocrotaline-Induced Pulmonary Hypertension


Transforming growth factor-β (TGF-β) inhibition is an investigational therapy for pulmonary arterial hypertension with promising results in experimental studies. The present work compared this approach with endothelin-receptor blockade and evaluated the effects of combined administration. Pulmonary arterial hypertension was induced by single monocrotaline injection (60 mg/kg) in 75 Wistar rats and 15 rats served as controls. Intervention groups consisted of treatment with an antibody against TGF-β-ligand, bosentan, both or none, initiated four weeks after monocrotaline injection. Right ventricular systolic pressure, pulmonary vascular remodeling, and exercise tolerance were evaluated eight weeks after monocrotaline injection. Either treatment, alone or in combination, lowered mortality. Comparable efficacy was found in the three treatment groups in terms of right ventricular systolic pressure (~45% decrease) and hypertrophy (~30% decrease), as well as exercise capacity. The three treatment groups equally ameliorated pulmonary vascular remodeling, evidenced by decreased vessel-wall thickness (in vessels 50–200 μm) and a smaller number of pre-∗∗∗capillary arterioles (< 50 μm) with a muscularized media. Treatment either with an antibody against TGF-β or with endothelin receptor blockade are equally effective in experimental pulmonary hypertension. Their combination provides no added benefit, indicating common mechanisms of action.

Read the full article online


Endothelin and Endothelium & Epithelium and Epithelial Transport
Growth Factors
Pulmonary Vascular Remodeling


Aikaterini J. Megalou, Chryssoula Glava, Agapi D. Vilaeti, Dimitrios L. Oikonomidis, Giannis G. Baltogiannis, Apostolos Papalois, Antonios P. Vlahos, Theofilos M. Kolettis

Published in:

Pulmonary Circulation Vol 2: No 4 cover image

December 2012

Pulmonary Circulation Vol 2: No 4

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI